Hikma Pharmaceuticals

Hikma is a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets it serves through the development, manufacturing and marketing of a broad range of solid, liquid and injectable generic and in-licensed pharmaceutical products.
Hikma is a leading generic pharmaceutical company with a significant presence in the Middle East and North Africa (MENA) region, the United States and Europe. It was first listed on the London Stock Exchange in 2005 is now a constituent of the FTSE 100 Index.

Type
Public
HQ
London, GB
Founded
1978
Size (employees)
7,189 (est)
Hikma Pharmaceuticals was founded in 1978 and is headquartered in London, GB

Hikma Pharmaceuticals Office Locations

Hikma Pharmaceuticals has offices in London, , Beirut, Cairo and in 3 other locations
London, GB
Riyadh, SA
Dubai, AE
Cairo, EG
Beirut, LB

Hikma Pharmaceuticals Metrics

Hikma Pharmaceuticals Summary

Market capitalization

£4.8 b

Closing share price

£21.3
Hikma Pharmaceuticals's current market capitalization is £4.8 b.

Hikma Pharmaceuticals Financials

Hikma Pharmaceuticals's revenue is £897.6 m in FY, 2013 which is a 12.9% decrease from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

£897.6 m£1 b£996.7 m

Revenue growth, %

14.8%(3.3%)

Cost of sales

£395.2 m£441.6 m£430.5 m

Gross profit

£502.4 m£589 m£566.2 m

Gross profit Margin, %

56%57.2%56.8%

Operating expense total

£270.9 m£310.8 m£302.5 m

Hikma Pharmaceuticals Market Value History

Hikma Pharmaceuticals Online Presence

Hikma Pharmaceuticals News

Hikma Pharmaceuticals Company Life

You may also be interested in